History
One of the earliest reasonably effective drug treatments for epilepsy did not emerge from a modern epilepsy trial. It grew out of nineteenth-century observation, imperfect theory and, eventually, stronger clinical evidence.
In 1857, Sir Charles Locock was reported as describing the use of potassium bromide in women whose seizures were thought to be linked to menstruation. Later historical review has shown that the famous account is more complicated than the simplified version often repeated in textbooks.
Locock’s reported results were striking, but other doctors did not immediately reproduce the same degree of success. The treatment might have faded from use had later clinicians not produced more convincing evidence that bromide really could reduce epileptic seizures.
Samuel Wilks and the evidence that followed
Historical analysis credits Samuel Wilks with providing important independent evidence for bromide’s antiseizure effect in 1861. That helped move bromide from an intriguing report towards broader clinical use.
For decades afterwards, bromides became central to epilepsy treatment. They were far from ideal: toxicity and adverse effects could be substantial, and treatment was based on medical assumptions very different from those used today. But this was still a turning point because it showed that recurrent seizures could be reduced pharmacologically.
Why the story matters
The bromide story is a reminder that medical progress is rarely tidy. Important treatments can emerge through observation and chance, then need years of testing, correction and better evidence before their real value becomes clear.
It also shows why historical claims need checking. Saying simply that one doctor “discovered the first epilepsy medicine” hides the uncertainty, failed replication and contributions of the clinicians who came afterwards.
Sources
Eadie — Sir Charles Locock and potassium bromide